Item does not contain fulltextTransplantation with histocompatible identical siblings is a curative treatment for patients with myelodysplastic syndromes (MDS). Alternative treatments, such as transplantation with other family donors, are an option for patients without HLA-identical siblings. This study evaluated transplantation with genotypically nonidentical family donors and compared the results to those obtained with unrelated donors and autologous stem cell transplantation. Overall 3-year survival was 35% for the 79 patients transplanted using genotypically nonidentical donors, DFS was 31%, relapse risk 16%, and the treatment-related mortality (TRM) 62%. Patients transplanted using phenotypically identical family donors had a significa...
International audienceRecently, haploidentical transplantation (haplo) using post-transplant cyclop...
To determine whether the risks of allogeneic transplantation are different when the donor is a fully...
Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the ou...
Transplantation with histocompatible identical siblings is a curative treatment for patients with my...
Transplantation with histocompatible identical siblings is a curative treatment for patients with my...
Allogeneic stem cell transplantation from an HLA-identical sibling donor is a curative treatment opt...
We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should b...
Item does not contain fulltextThe only curative treatment in patients with intermediate or high-risk...
Item does not contain fulltextAllogeneic hematopoietic stem cell transplantation is the only curativ...
Allogeneic stem cell transplantation (alloSCT) is the treatment of choice in the majority of young p...
Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has b...
We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation ...
Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has b...
Background: Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosi...
AbstractRecent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell t...
International audienceRecently, haploidentical transplantation (haplo) using post-transplant cyclop...
To determine whether the risks of allogeneic transplantation are different when the donor is a fully...
Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the ou...
Transplantation with histocompatible identical siblings is a curative treatment for patients with my...
Transplantation with histocompatible identical siblings is a curative treatment for patients with my...
Allogeneic stem cell transplantation from an HLA-identical sibling donor is a curative treatment opt...
We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should b...
Item does not contain fulltextThe only curative treatment in patients with intermediate or high-risk...
Item does not contain fulltextAllogeneic hematopoietic stem cell transplantation is the only curativ...
Allogeneic stem cell transplantation (alloSCT) is the treatment of choice in the majority of young p...
Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has b...
We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation ...
Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has b...
Background: Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal prognosi...
AbstractRecent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell t...
International audienceRecently, haploidentical transplantation (haplo) using post-transplant cyclop...
To determine whether the risks of allogeneic transplantation are different when the donor is a fully...
Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the ou...